Want to see QNRX full AI Analyst Report?
QNRX Stock Chart & Stats
$5.07
-$0.09(-2.06%)
At close: 4:00 PM EDT
$5.07
-$0.09(-2.06%)
Day’s Range― - ―
52-Week Range$3.25 - $23.50
Previous Close$4.1
Volume6.33K
Average Volume (3M)51.09K
Market Cap
$8.01M
Enterprise Value-$1.08M
Total Cash (Recent Filing)$10.80M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.59
Next Earnings
Nov 05, 2026EPS Estimate
-1.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.89
Shares Outstanding4,804,161
10 Day Avg. Volume53,067
30 Day Avg. Volume51,095
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.65
Price to Sales (P/S)0.00
P/FCF Ratio-1.60
Enterprise Value/Market Cap-0.13
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit42.44
Enterprise Value/Ebitda0.06
Forecast
1Y Price Target
$21.40Price Target Upside322.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-6.39
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EvidenceQRX003 has generated encouraging early efficacy and safety signals across a pediatric case and interim Phase 2/3 results. While not definitive, this evidence supports development momentum and the possibility of addressing a severe condition with no approved Netherton-specific treatment.
Regulatory PositioningOrphan designation strengthens QRX003’s development and commercial pathway by providing regulatory support, fee reductions, possible grants, and potential market exclusivity. These benefits could improve the asset’s long-term strategic value if clinical and marketing approvals are achieved.
Debt-free Balance SheetThe absence of reported debt limits interest obligations and reduces refinancing pressure while the company funds clinical development. This gives management more flexibility than a similarly loss-making, leveraged biotech, although operating cash needs remain substantial.
Bears Say
No Commercial RevenueQuoin remains entirely dependent on development-stage assets rather than an established commercial product base. With no reported revenue, the company has not demonstrated market monetization, making future value dependent on successful trials, approvals, and eventual launch execution.
Accelerating Cash BurnIncreasing cash outflows raise the funding requirement for ongoing trials and corporate operations. Sustained negative free cash flow can force repeated financing or slower development if capital becomes less available, making liquidity management a durable constraint on execution.
Shrinking Financial BaseThe sharp contraction in equity and assets reflects accumulated losses and ongoing cash consumption, weakening the company’s financial cushion. This erosion increases reliance on external capital and can constrain strategic flexibility even though reported debt remains absent.
Quoin Pharmaceuticals News
QNRX FAQ
What was Quoin Pharmaceuticals’s price range in the past 12 months?
Quoin Pharmaceuticals lowest stock price was $3.25 and its highest was $23.50 in the past 12 months.
What is Quoin Pharmaceuticals’s market cap?
Quoin Pharmaceuticals’s market cap is $8.01M.
When is Quoin Pharmaceuticals’s upcoming earnings report date?
Quoin Pharmaceuticals’s upcoming earnings report date is Nov 05, 2026 which is in 14 days.
How were Quoin Pharmaceuticals’s earnings last quarter?
Quoin Pharmaceuticals released its earnings results on Aug 14, 2026. The company reported -$1.9 earnings per share for the quarter, missing the consensus estimate of -$1.61 by -$0.29.
Is Quoin Pharmaceuticals overvalued?
According to Wall Street analysts Quoin Pharmaceuticals’s price is currently Undervalued.
Does Quoin Pharmaceuticals pay dividends?
Quoin Pharmaceuticals does not currently pay dividends.
What is Quoin Pharmaceuticals’s EPS estimate?
Quoin Pharmaceuticals’s EPS estimate is -1.52.
How many shares outstanding does Quoin Pharmaceuticals have?
Quoin Pharmaceuticals has 4,804,161 shares outstanding.
What happened to Quoin Pharmaceuticals’s price movement after its last earnings report?
Quoin Pharmaceuticals reported an EPS of -$1.9 in its last earnings report, missing expectations of -$1.61. Following the earnings report the stock price went down -15.868%.
Which hedge fund is a major shareholder of Quoin Pharmaceuticals?
Currently, no hedge funds are holding shares in QNRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Quoin Pharmaceuticals
Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.
QNRX Stock 12 Month Forecast
Average Price Target
$21.40
▲(322.09% Upside)
Technical Analysis
―
Jaguar Animal Health
―
Adial Pharmaceuticals
―
Alzamend Neuro
―
Calidi Biotherapeutics
―
Ownership Overview
3.80% Insiders
32.55% Other Institutional Investors
63.64% Public Companies and
Individual Investors